Search

everythinglearnresearchcommunity

for

Search:↓

IL-17 plays a key role in severe hair loss in chronic alopecia areata.

A virus protein can activate a pathway that may lead to abnormal hair follicle development.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Potential therapeutic targets for scarring hair loss are identified.

Regulatory T cells protect hair follicle stem cells by maintaining immune privilege in the skin.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

BTNL proteins help control inflammatory bowel disease by maintaining specific immune cells.

Immune cells affect hair growth and could lead to new hair loss treatments.

The CD44-CD49d complex boosts T cell activation and survival in autoimmune disease.

TNC+ fibroblasts play a key role in skin inflammation by interacting with T cells.

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.

Repeated biopsies are crucial for managing lupus panniculitis when initial treatments fail.

An 8-year-old girl developed a rare skin condition in a linear pattern on one side of her body after a lung infection, which improved with treatment.

Skin bacteria can help wound healing by activating certain immune cells.

CD3+ T-cell presence is a reliable marker to tell apart alopecia areata from pattern hair loss.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

Rare changes in the KRT82 gene are linked to a higher risk of Alopecia Areata.

ILC1 cells contribute to hair loss in alopecia areata.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

Understanding how Regulatory T Cells work could help create treatments for certain skin diseases and cancers.

Fetal skin has unique immune cells different from adult skin.

Patients with RASopathies have a higher risk of autoimmune disorders and should be routinely screened.

People with alopecia areata have fewer regulatory T-cells than those with other skin conditions.

Folliculotropic mycosis fungoides can occur in children and is diagnosed with specific tests, but often stays in early stages with treatment.

Vδ1+ T-cells in the skin contribute to hair loss in alopecia areata and could be targeted for treatment.

The paper concludes that the patchiness of alopecia areata is likely due to when the immune attack happens in the hair growth cycle.

Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.

Targeting mTOR in myeloid cells may help reduce psoriasis symptoms.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.